tocilizumab in the treatment of systemic inflammatory response in a patient with CoVID-19 (clinical case)
https://doi.org/10.22625/2072-6732-2020-12-3-90-93
Abstract
Improving the approaches to treating COVID-19 infection opens up the possibility for using previously known groups of drugs that demonstrate their effectiveness in the pathogenetic treatment of this disease.
Significant clinical experience in the field of treatment of COVID-19 have been accumulated in Clinical Infectious Diseases Hospital named after S.P. Botkin, Saint-Petersburg, Russia. The case study demonstrates the timeliness and effectiveness of anticytokine therapy with COVID-19, the possibility of using a recombinant humanized monoclonal antibody to the human receptor for interleukin-6 (IL-6) (tocilizumab).
About the Authors
D. D. Avdoshina
Clinical Infectious Hospital named after S.P. Botkin
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
A. G. Dyachkov
Clinical Infectious Hospital named after S.P. Botkin; First Saint-Petersburg State Medical University named after аcademician I.P. Pavlov
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
D. A. Gusev
Clinical Infectious Hospital named after S.P. Botkin; First Saint-Petersburg State Medical University named after аcademician I.P. Pavlov
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
References
1. CDC. 2019 Novel Coronavirus, Wuhan, China. Centers for Disease Control and Prevention.. 2020 Jan 26; Accessed: March 25, 2020.
2. McCreary E.K., Pogue JM. COVID-19 Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases (OFID). 2020 Mar; 23.
3. Alhazzani W., Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019. COVID-19. Critical Care Medicine. 2020 Mar.
4. Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 Apr; 13.
5. Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. Pharmacotherapy. 2020 Apr; 7.
6. Cinzerling V. A. Voprosy patomorfogeneza novoj koronavirusnoj infekcii (COVID-19) / V.A. Cinzerling, M.A. Vashukova, M.V. Vasil’eva, A.N. Isakov i dr. // Zhurnal infektologii. – 2020. –V.12, №2 – S.5-11
7. Bhimraj A. Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. 2020 Apr; 13
8. FDA clears investigational new drug application for Mesoblast to use remestemcel-L in patients with acute respiratory distress syndrome caused by COVID-19. Mesoblast Ltd. 2020 Apr; 06.
9. First patients dosed in phase 2/3 randomized controlled trial of Mesoblast’s remestemcel-l for COVID-19 acute respiratory distress syndrome. Mesoblast Ltd. 2020 May; 6.
10. Genentech initiates phase III clinical trial of Actemra plus remdesivir in hospitalized patients with severe COVID-19 pneumonia. Genentech. 2020 May; 27.
11. National Health Commission (NHC) of the People’s Republic of China. The diagnosis and treatment guide of COVID-19 pneumonia caused by new coronavirus infection 7th Edition. 2020 Mar; 3.
Review
For citations:
Avdoshina D.D., Dyachkov A.G., Gusev D.A. tocilizumab in the treatment of systemic inflammatory response in a patient with CoVID-19 (clinical case). Journal Infectology. 2020;12(3):90-93. (In Russ.) https://doi.org/10.22625/2072-6732-2020-12-3-90-93
Views:
1018
.png)
.png)
Email this article 